Press Releases / Stock Exchange Intimation

Date Title   Report

01 Aug 2020 SE Intimation on Newspaper Advertsiment Petition hearing PDF 842 KB
05 Aug 2020 Newspaper advertisement on results PDF 842 KB
05 Aug 2020 Strides Outcome of the BM Results PDF 2.26 MB
05 Aug 2020 Strides intimation allotment of shares PDF 102 KB
30 Jul 2020 Strides Intimation of Advertisment on Board Meeting PDF 1.21 MB
30 Jul 2020 Strides Intimation of Advertisment AGM Notice and Annual Report PDF 2.71 MB
29 Jul 2020 Strides Book Closure for AGM PDF 149 KB
29 Jul 2020 Notice of 29th Annual General Meeting and Annual Report for FY 2019-2020 PDF 3.87 MB
29 Jul 2020 Intimation of Board Meeting for quarter ended June 30, 2020 PDF 169 KB
18 Jul 2020 Newspaper advertisement titled ‘29th AGM to be held over video conference, record date and final dividend information’ PDF 430 KB
15 Jul 2020 29th Annual General Meeting / Record date PDF 209 KB
09 Jul 2020 Strides receives USFDA approval for Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules PDF 309 KB
20 Jun 2020 Shareholding pattern PDF 264 KB
19 Jun 2020 NCLT Order of Blore Bench Merger of WoS PDF 168 KB
18 Jun 2020 Disclosure of Related Party Transactions for the year ended March 31, 2020 PDF 276 KB
02 Jun 2020 Strides receives USFDA approval for Triamcinolone Acetonide Ointment PDF 299 KB
22 May 2020 Strides SE Intimation PDF 143 KB
20 May 2020 Outcome of Board Meeting Results PDF 3.36 MB
20 May 2020 Outcome of Board Meeting - Final Dividend PDF 126 KB
20 May 2020 Allotment of shares under ESOP PDF 127 KB
20 May 2020 Grant of Stock Options PDF 970 KB
13 May 2020 Newspaper Advertisment - Intimation of Board Meeting PDF 970 KB
11 May 2020 Intimation of Board Meeting for considering audited results PDF 213 KB
29 Apr 2020 Strides develops and commences export of Favipiravir Antiviral Tablets PDF 327 KB
20 Apr 2020 Strides receives USFDA approval for Flucytosine Capsules PDF 256 KB
02 Apr 2020 Strides provides updates as USFDA requests all manufacturers to withdraw Ranitidine products from the US Market PDF 283 KB
31 Mar 2020 Shareholding Pattern PDF 263 KB
30 Mar 2020 Strides announces successful completion of US FDA inspection conducted in January 2020 at flagship facility in Bangalore PDF 256 KB
26 Mar 2020 EIR from USFDA on continued GMP status for the flagship facility in Bangalore PDF 148 KB
04 Mar 2020 Strides receives USFDA approval for Tetracycline Hydrochloride Capsules PDF 236 KB
21 Feb 2020 Outcome of NCLT Meeting PDF 661 KB
07 Feb 2020 Strides to acquire 18 ANDAs from Pharmaceutics International, Inc. PDF 300 KB
31 Jan 2020 Intimation of Investors / Analysts Meet PDF 230 KB
30 Jan 2020 SE Intimation Scheme of Amalgamation PDF 492 KB
30 Jan 2020 Outcome of Board Meeting Results PDF 4.16 MB
30 Jan 2020 SE Intimation allotment of shares - ESOP PDF 106 KB
28 Jan 2020 Strides Earnings Call Invite PDF 174 KB
24 Jan 2020 Strides announces the successful completion of US FDA inspection at its Alathur facility with “Zero 483 observations” PDF 269 KB
24 Jan 2020 USFDA tentative approval for Triamcinolone Acetonide Ointment PDF 169 KB
23 Jan 2020 Intimation of Newspaper Advertisment on Board Meeting PDF 276 KB
23 Jan 2020 Intimation of Board Meeting PDF 93 KB
20 Jan 2020 Newspaper Publication on NCLT Meeting PDF 1.43 MB
20 Jan 2020 Strides announces successful closure of the USFDA inspection at its manufacturing site in Florida, United States PDF 1.19 MB
17 Jan 2020 SPSL Intimation to SE Tribunal Meeting PDF 7.86 MB
16 Jan 2020 USFDA approval for Loratadine OTC Softgel Capsules PDF 178 KB
08 Jan 2020 Dr. R Ananthanarayanan appointed as the new CEO & Managing Director of Strides PDF 212 KB
08 Jan 2020 Press Release on appointment of new CEO & MD PDF 251 KB
08 Jan 2020 SE Intimation on appointment of new CEO & MD PDF 63 KB
08 Jan 2020 SE Intimation on KMP PDF 83 KB
Date Title   Report

31 Dec 2019 Shareholding pattern for the quarter ended 31 Dec 2019 PDF 4.3 MB
11 Dec 2019 Intimation on Appointment of ID PDF 64 KB
05 Dec 2019 Intimation of Investor/ Analyst Day PDF 147 KB
04 Dec 2019 USFDA tentative approval for Diclofenac Potassium Softgel Capsules PDF 406 KB
25 Nov 2019 Outcome of Postal Ballot – CG to Stelis PDF 1.06 MB
22 Nov 2019 Disclosure of Related Party Transactions for the half year ended September 30, 2019 PDF 227 KB
08 Nov 2019 Strides announces relaunch of Ranitidine tablets (Rx) for the US Market PDF 402 KB
06 Nov 2019 Intimation SE Merger of WoS PDF 1.67 MB
04 Nov 2019 Strides’ Ranitidine Tablets 300 mg lots tested by USFDA are within the acceptable NDMA limits PDF 181 KB
25 Oct 2019 Outcome of Board Meeting of Oct 25, 19 - Allotment of shares PDF 421 KB
25 Oct 2019 Outcome of Board Meeting of Oct 25, 19_Grant of Options PDF 50 KB
25 Oct 2019 Outcome of Board Meeting of Oct 25, 19 - Unaudited results PDF 3.01 MB
25 Oct 2019 SPSL Earnings Call Intimation PDF 176 KB
23 Oct 2019 TGA, Australia announces Ranitidine test results PDF 421 KB
23 Oct 2019 EIR from USFDA on continued GMP status for formulation facility at Alathur PDF 146 KB
22 Oct 2019 SE Intimation of Postal Ballot and Evoting PDF 870 KB
18 Oct 2019 Intimation of Board Meeting for quarter ended Sep 2019 PDF 92.9 KB
04 Oct 2019 Update on Encumbrance by Promoters PDF 1.98 MB
30 Sep 2019 Shareholding pattern for the quarter ended 30 September 2019 PDF 304 KB
27 Sep 2019 Strides receives USFDA approval for Solifenacin Succinate Tablets PDF 304 KB
27 Sep 2019 Further Updates on Ranitidine Tablets for the US Markets PDF 146 KB
25 Sep 2019 Update on Ranitidine tablets PDF 224 KB
20 Sep 2019 Strides Board approves incremental investments in Stelis PDF 316 KB
20 Sep 2019 Strides Board approves incremental investments in Stelis PDF 227 KB
20 Sep 2019 Grant of Options under Strides Employee Stock Option Plan 2016 PDF 52 KB
11 Sep 2019 Strides acquires strategic stake in Fairmed Healthcare AG in Europe PDF 320 KB
27 Aug 2019 Strides acquires USFDA approved manufacturing facility in the US PDF 349 KB
09 Aug 2019 Successful completion of US FDA inspection at its Alathur facility with "Zero 483 observations" PDF 1.4 MB
08 Aug 2019 Intimation of Newspaper Advertisment - Interim Divided PDF 144 KB
31 Jul 2019 Intimation on proceeding of 28th AGM – July 30, 2019 PDF 174 KB
31 Jul 2019 Outcome of 28th AGM – July 30, 2019 PDF 1.64 MB
31 Jul 2019 Update PDF 125 KB
29 Jul 2019 Strides Outcome of the BM PDF 3.19 MB
29 Jul 2019 SE Intimation Grant of Options PDF 55 KB
29 Jul 2019 Strides Outcome of the BM - Dividend PDF 57 KB
29 Jul 2019 SPSL 2019 Merger-Intimation to SE PDF 175 KB
29 Jul 2019 Strides JVin Hong Kong PDF 158 KB
29 Jul 2019 Strides Board Meeting Outcome PDF 3.18 MB
29 Jul 2019 Strides Outcome of the BM Interim Dividend PDF 57 KB
29 Jul 2019 SPSL Earnings Call Intimation PDF 175 KB
26 Jul 2019 Intimation of Newspaper Advertisment - Q1 Meeting FY 20 PDF 868 KB
23 Jul 2019 Intimation of Board Meeting for Q1 FY 2020 PDF 94 KB
23 Jul 2019 EIR from USFDA on continued GMP status for the flagship facility in Bangalore PDF 132 KB
20 Jul 2019 Strides announces successful completion of US FDA inspection at its flagship facility in Bangalore PDF 217 KB
17 Jul 2019 Clarification on the Article appeared in Economic Times on July 17, 2019 PDF 333 KB
10 Jul 2019 Update on “Strides announces final closure of Arrow transaction" PDF 133 KB
08 Jul 2019 SE Intimation - newspaper advertisment on AGM PDF 538 KB
05 Jul 2019 SE Intimation - Book closure intimation and Record date PDF 49 KB
05 Jul 2019 SE Intimation - AGM Notice and Annual Report for FY 18-19 PDF 4.13 MB
02 Jul 2019 Update relating to “USFDA classifies Strides Puducherry facility as Official Action Indicated (OAI)”. PDF 129 KB
01 Jul 2019 Update on “Strides to exit its investment in Arrow for AUD 394 Million" PDF 128 KB
30 Jun 2019 Shareholding pattern for the quarter ended 30 june 2019 PDF 186 KB
08 Jun 2019 Disclosure of Related Party Transactions for the half year ended March 31, 2019 PDF 285 KB
05 Jun 2019 Notice for transferring of equity shares to Investor Education and Protection Fund (IEPF) PDF 427 KB
21 May 2019 Annual Secretarial Compliance Report for the year ended March 31, 2019 PDF 1.26 MB
10 May 2019 Audited Financial Results PDF 2.2 MB
10 May 2019 Declaration of Final Dividend PDF 117 KB
10 May 2019 SPSL Earnings Call Intimation PDF 175 KB
06 May 2019 USFDA classifies Strides Puducherry facility as Official Action Initiated (OAI) PDF 146 KB
04 May 2019 Board Meeting for Consideration of Audited Financial Results for the quarter and year ended March 31, 2019 PDF 89 KB
03 May 2019 Vivimed Life Sciences Private Limited (VLSPL) issues voluntary recall of 19 lots of Losartan Pottasium Tablets in USA due to detection of trace amount of N-Nitriso-N-methyl-4-aminobutyric acid (NMBA) impurity. These lots were manufactured at VLSPL's Alathur facility prior to acquisition by Strides PDF 535 KB
04 Apr 2019 Strides pharma intimation on window closure PDF 89 KB
02 Apr 2019 Receipt of Establishment Inspection Report (EIR) from US FDA for Singapore facility PDF 997 KB
02 Apr 2019 Strides to launch Potassium Chloride Extended-Release Tablets in the US market PDF 997 KB
01 Apr 2019 Amendment to the Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information PDF 350 KB
31 Mar 2019 Strides Shareholding pattern PDF 4 MB
27 Mar 2019 USFDA approval for its greenfield oral dosage facility in Singapore PDF 170 KB
20 Feb 2019 USFDA approval for Ethosuximide Softgel Capsules PDF 187 KB
13 Feb 2019 USFDA approval for Triamcinolone Acetonide Cream PDF 181 KB
06 Feb 2019 EIR from USFDA on continued GMP status for the flagship facility in Bangalore PDF 177 KB
29 Jan 2019 Outcome of Board meeting PDF 2.03 MB
29 Jan 2019 Strides to exit its investment in Arrow PDF 328 KB
29 Jan 2019 Strides to acquire 80% stake in Pharmapar Inc. PDF 329 KB
29 Jan 2019 Strides to acquire 100% stake in Vensun Pharmaceuticals, Inc PDF 326 KB
29 Jan 2019 SPSL Earnings Call Intimation PDF 98 KB
25 Jan 2019 Strides to convert its 50:50 JV with Vivimed to 100% ownership PDF 371 KB
22 Jan 2019 Announcement of Board Meeting PDF 124 KB
Date Title   Report

31 Dec 2018 Shareholding pattern for the quarter ended 31 December 2018 PDF 4 MB
24 Dec 2018 USFDA approval for Polyethylene Glycol 3350 and Electrolytes for Oral Solution PDF 185 KB
19 Dec 2018 Strides and Mylan to release General Claims Escrow on Agila transaction Strides to receive ~US$ 42 Mn immediately from General Claims Escrow PDF 160 KB
12 Dec 2018 USFDA approval for Lidocaine Ointment PDF 182 KB
11 Dec 2018 Strides Vivimed JV receives approval for Albendazole Tablets PDF 158 KB
22 Nov 2018 Updates on Strides investments in Stelis Biopharma PDF 147 KB
09 Nov 2018 Strides enters into a strategic partnership with SUDA Pharmaceuticals for the US market PDF 172 KB
02 Nov 2018 Successful completion of US FDA inspection at its flagship facility in Bangalore PDF 139 KB
31 Oct 2018 Press Release on CHC PDF 1.12 MB
31 Oct 2018 Outcome of Board Meeting PDF 3.78 MB
25 Oct 2018 Intimation on Board Meeting for quarter ended September 2018 PDF 91.8 KB
24 Oct 2018 SPSL Earnings Call Intimation PDF 147 KB
20 Oct 2018 US FDA Approval for Gabapentin Capsules PDF 115 KB
30 Sep 2018 Shareholding Pattern for the Quarter ended 30 September 2018 PDF 3.45 MB
25 Sep 2018 27th Annual General Meeting Outcome - Voting Results & Scrutinizer Report PDF 2.18 MB
25 Sep 2018 27th Annual General Meeting Proceedings PDF 605 KB
20 Sep 2018 ACCC announces clearance of the merger of Arrow Pharmaceuticals and Apotex Australia & NZ PDF 867 KB
18 Sep 2018 Completion of USFDA inspection at Bangalore facility PDF 529 KB
05 Sep 2018 USFDA Approval - Potassium Chloride Extended Release Tablets PDF 776 KB
31 Aug 2018 Update on divestment of Strides Chemicals Private Limited, API asset at Ambernath PDF 117 KB
31 Aug 2018 SE Intimation Notice of AGM and Book closure intimation PDF 169 KB
22 Aug 2018 Strides receives acceptance from USFDA for two key ANDAs under newly introduced Competitive Generic Therapy PDF 463 KB
08 Aug 2018 Grant of Options under Strides Shasun ESOP 2016 PDF 70 KB
08 Aug 2018 Outcome of Board meeting PDF 12 MB
08 Aug 2018 SPSL Earnings Call Intimation PDF 104 KB
31 Jul 2018 Intimation of Board Meeting for quarter ended June 30, 2018 PDF 122 KB
20 Jul 2018 Change in name of the Company to 'STRIDES PHARMA SCIENCE LIMITED'  PDF 126.3 KB
02 Jul 2018 Outcome of Postal Ballot PDF 1.44 MB
02 Jul 2018 USFDA tentative approval for Milnacipran Hydrochloride Tablets PDF 76 KB
02 Jul 2018 USFDA approval for Ibuprofen OTC Tablets PDF 82 KB
30 Jun 2018 Shareholding Pattern PDF 3.46 MB
26 Jun 2018 SE Intimation listing of shares issued by Solara PDF 47 KB
21 Jun 2018 Strides Shasun’s Rectal Artesunate Product Receives WHO Prequalification PDF 70 KB
19 June 2018 Strides Shasun receives USFDA approval for Ketoconazole Tablets USP, 200mg PDF 67.7 KB
11 Jun 2018 Strides Shasun receives USFDA approval for Oseltamivir Phosphate Capsules PDF 75 KB
06 Jun 2018 Strides Shasun SE Intimation on transfer of shares IEPF PDF 277 KB
29 May 2018 Strides Shasun Intimation in Newspaper PDF 512 KB
29 May 2018 Strides Shasun SE Intimation Clarification on Rumour PDF 512 KB
18 May 2018 Strides Shasun Intimation of Postal Ballot and Evoting PDF 1 MB
18 May 2018 Intimation to SE Merger of WOS PDF 171 KB
18 May 2018 Intimation to SE Board Reconstitution PDF 71 KB
18 May 2018 Strides Shasun Outcome of Board Meeting PDF 6 MB
18 May 2018 Strides Shasun_Recommendation of final dividend PDF 48 KB
17 May 2018 SSL Earnings Call Intimation PDF 115 KB
11 May 2018 Announcement of Board Meeting to be held on May 18, 2018 PDF 36 KB
09 May 2018 Strides & Apotex agree to merge their Australian businesses PDF 80 KB
02 May 2018 USFDA approval for Cinacalcet Hydrochloride Tablets PDF 74 KB
24 Apr 2018 Strides Shasun to divest its holding in remaining API asset at Ambernath PDF 150 KB
20 Apr 2018 Intimation to SE on cost of acquisition PDF 220 KB
12 Apr 2018 USFDA Approval for Cyproheptadine Hydrochloride Tablets PDF 74 KB
12 Apr 2018 Intimation on allotment of shares by Solara Active PDF 114 KB
02 Apr 2018 USFDA Approval For Ibuprofen Softgel OTC Capsules PDF 72 KB
31 Mar 2018 Shareholding Pattern PDF 4MB
26 Mar 2018 Strides Shasun Intimation on Effective Date and Record Date for allotment PDF 120 KB
23 Mar 2018 SE Intimation - Receipt of NCLT Order relating to Demerger of Commodity API Business PDF 111 KB
14 Mar 2018 USFDA Approval for Efavirenz Tablet PDF 67 KB
12 Mar 2018 Intimation on appointment of Arun Kumar as KMP PDF 55.6 KB
12 Mar 2018 Intimation on appointmentof Arun Kumar as Executive Chairman PDF 50.7 KB
07 Mar 2018 Strides Shasun to launch Ranitidine 75mg OTC Tablets PDF 70 KB
26 Feb 2018 Strides Shasun to launch Ranitidine OTC Tablets PDF 119 KB
09 Feb 2018 Press Release – Q3 FY 18 PDF 132 KB
09 Feb 2018 SSL_Consol Q3 FY 18 Financials PDF 304 KB
09 Feb 2018 SSL_Standalone Q3 FY 18 Financials PDF 124 KB
09 Feb 2018 Outcome of Board Meeting - Unaudited Financial Results for Dec 31, 2017 PDF 2 MB
09 Feb 2018 Allotment of shares under ESOP 2015 PDF 135 KB
09 Feb 2018 Newspaper Advertisement on hearing of petition PDF 3 MB
09 Feb 2018 SSL Earnings Call Intimation PDF 115 KB
05 Feb 2018 Clarification on Article appeared in Economic Times on February 5, 2018 titled “Blackstone, Strides, Nectar Lead Race for Orchid Pharma” PDF 662 KB
03 Feb 2018 Intimation of Board Meeting for Q3 FY 17-18 PDF 124 KB
31 Jan 2018 USFDA Approval for Nystatin and Triamcinolone Acetonide Ointment PDF 72 KB
31 Jan 2018 USFDA Approval for Piroxicam capsules PDF 65 KB
29 Jan 2018 USFDA Approval for Tenofovir Disoproxil Fumarate tablets PDF 75 KB
19 Jan 2018 Update on ‘Strides Shasun acquires controlling stake in Trinity Pharma, South Africa’ PDF 152 KB
Date Title   Report

31 Dec 2017 Shareholding Pattern Shareholding Pattern PDF 906 KB
28 Dec 2017 Strides Shasun approval for composite scheme Strides Shasun approval for composite scheme PDF 2 MB
20 Dec 2017 Acquisition of Trinity Pharma Acquisition of Trinity Pharma PDF 239 KB
04 Dec 2017 Update on ‘Divestment of India brand business to Eris Lifesciences’ Update on ‘Divestment of India brand business to Eris Lifesciences’ PDF 185 KB
22 Nov 2017 USFDA Approval for Acetazolamide Tablets USFDA Approval for Acetazolamide Tablets PDF 78 KB
18 Nov 2017 Strides Shasun divests India brand business to Eris Lifesciences Strides Shasun divests India brand business to Eris Lifesciences PDF 625 KB
31 Oct 2017 Press Release – Q2 FY 18 Press Release – Q2 FY 18 PDF 242 KB
31 Oct 2017 SSL_Consol Q2 FY 18 Financials SSL_Consol Q2 FY 18 Financials PDF 307 KB
31 Oct 2017 SSL_Standalone Q2 FY 18 Financials SSL_Standalone Q2 FY 18 Financials PDF 135 KB
31 Oct 2017 Strides Shasun Stock Exchange Intimation Post Meeting Strides Shasun Stock Exchange Intimation Post Meeting PDF 1 MB
31 Oct 2017 SSL - Intimation to SE on Meger of WoS SSL - Intimation to SE on Meger of WoS PDF 239 KB
31 Oct 2017 Letter to SE_Allotment of shares under ESOP 2015 Letter to SE_Allotment of shares under ESOP 2015 PDF 44 KB
30 Oct 2017 SSL Earnings Call Intimation SSL Earnings Call Intimation PDF 45 KB
27 Oct 2017 Strides Shasun SE Intimation Strides Shasun SE Intimation PDF 42 KB
25 Oct 2017 Strides Shasun Announcement of Board Meeting Strides Shasun Announcement of Board Meeting PDF 44 KB
30 Sep 2017 Shareholding Pattern Shareholding Pattern 30 September 2017 PDF 3 MB
20 Sep 2017 USFDA Approval for Omega-3-Acid Ethyl Esters capsules USFDA Approval for Omega-3-Acid Ethyl Esters capsules PDF 55 KB
15 Sep 2017 Outcome of 26 th AGM - Disclosure under SEBI LODR Outcome of 26<sup>th</sup> AGM - Disclosure under SEBI LODR PDF 289 KB
15 Sep 2017 Voting Results and Scrutinizer Report of 26 th AGM Voting Results and Scrutinizer Report of 26<sup>th</sup> AGM PDF 1.23 MB
12 Sep 2017 USFDA Approval for Potassium Citrate Extended-Release Tablets USFDA Approval for Potassium Citrate Extended-Release Tablets PDF 60 KB
01 Sep 2017 EIR from US FDA on continued GMP status for flagship KRSG facility in Bangalore. EIR from US FDA on continued GMP status for flagship KRSG facility in Bangalore PDF 40 KB
31 Aug 2017 Arrow Pharmaceuticals acquires Amneal Pharmaceuticals in Australia Arrow Pharmaceuticals acquires Amneal Pharmaceuticals in Australia PDF 58 KB
31 Aug 2017 Intimation in newspaper advertisement on AGM notice Intimation in newspaper advertisement on AGM notice PDF 445 KB
24 Aug 2017 Notice of 26 th AGM Notice of 26<sup>th</sup> AGM PDF 1.36 MB
11 Aug 2017 SSL_Consol Q1 FY 18 Financials SSL_Consol Q1 FY 18 Financials PDF 107 KB
11 Aug 2017 SSL Standalone Q1 FY 18 Financials. SSL Standalone Q1 FY 18 Financials PDF 92 KB
11 Aug 2017 Press Release – Q1 FY 18 Press Release – Q1 FY 18 PDF 160 KB
24 July 2017 USFDA Approval for Cetirizine Softgel Capsules USFDA Approval for Cetirizine Softgel Capsules PDF 56.3 KB
03 July 2017 USFDA Approval for Promethazine HCL Tablets USFDA Approval for Promethazine HCL Tablets PDF 74.5 KB
30 June 2017 SSL Shareholding Pattern SSL Shareholding Pattern PDF 720 KB
30 June 2017 CCI Approval for the Scheme CCI Approval for the Scheme PDF 40.1 KB
22 June 2017 Update on transaction - Vivimed Labs Update on transaction - Vivimed Labs PDF 32.7 KB
12 June 2017 Clarification on Article appeared in online edition of Mint Clarification on Article appeared in online edition of Mint PDF 34.3 KB
12 June 2017 Analyst investors meet schedule Analyst investors meet schedule PDF 60.4 KB
12 June 2017 USFDA Approval for Amantadine Hydrochloride Tablets USFDA Approval for Amantadine Hydrochloride Tablets PDF 51.6 KB
08 June 2017 USFDA Approval for Amantadine Hydrochloride Capsules USFDA Approval for Amantadine Hydrochloride Capsules PDF 49.7 KB
07 June 2017 Strides Shasun SE Intimation Update on Credit Rating Strides Shasun SE Intimation Update on Credit Rating PDF 26.7 KB
01 June 2017 USFDA Approval For Ibuprofen Tablets USFDA Approval For Ibuprofen Tablets PDF 54.6 KB
29 May 2017 Completion of USFDA inspection at Bangalore Facility Completion of USFDA inspection at Bangalore Facility PDF 31.7 KB
26 May 2017 Strides Shasun Declaration Pursuant to Reg 33 of SEBI LODR Strides Shasun Declaration Pursuant to Reg 33 of SEBI LODR PDF 47.5 KB
24 May 2017 USFDA Approval for Memantine Tablets USFDA Approval for Memantine Tablets PDF 50.1 KB
18 May 2017 Auditors appointment Auditors appointment PDF 82.1 KB
18 May 2017 SE Intimation Grant of Options SE Intimation Grant of Options PDF 40.4 KB
18 May 2017 Strides Shasun Board Reconstitution Strides Shasun Board Reconstitution PDF 191 KB
18 May 2017 Strides Shasun Vivimed JV 18 May 2017 Strides Shasun Vivimed JV 18 May 2017 PDF 147 KB
18 May 2017 SSL - Consol FY 17 Financials SSL - Consol FY 17 Financials PDF 218 KB
18 May 2017 SSL - Standalone FY 17 Financials SSL - Standalone FY 17 Financials PDF 153 KB
18 May 2017 Press Release – FY 17 Press Release – FY 17 PDF 208 KB
17 May 2017 SSL Earnings Call Intimation SSL Earnings Call Intimation PDF 47.1 KB
11 May 2017 Strides Shasun announcement of Board Meeting Strides Shasun announcement of Board Meeting PDF 42.8 KB
05 May 2017 Successful completion of third consecutive US FDA inspection with ‘Zero 483 Status’ over the last month 5 May 2017 Successful completion of third consecutive US FDA inspection with ‘Zero 483 Status’ over the last month 5 May 2017 PDF 66.8 KB
04 May 2017 Strides Shasun SE Intimation Strides Shasun SE Intimation PDF 40.2 KB
28 Apr 2017 Strides Shasun SE Announcement Strides Shasun SE Announcement PDF 267 KB
24 Apr 2017 Strides Shasun SE Intimation Strides Shasun SE Intimation PDF 39.1 KB
06 Apr 2017 Strides Shasun SE Intimation Dowmload PDF PDF 38.9 KB
31 Mar 2017 Shareholding pattern 31 st March 2017 Shareholding pattern PDF 804 KB
27 Mar 2017 Strides Shasun SE Claratification Strides Shasun SE Claratification PDF 44.4 KB
22 Mar 2017 Scrutinizer Report_Capping of Strides’ investment in Stelis Scrutinizer Report_Capping of Strides’ investment in Stelis PDF 545 KB
20 Mar 17 Outcome of Board Meeting De-merger of Commodity API biz Outcome of Board Meeting De-merger of Commodity API biz PDF 184 KB
28 Feb 17 Postal ballot newspaper advertisment Postal ballot newspaper advertisment PDF 886 KB
21 Feb 17 Intimation of Postal Ballot & E-Voting Intimation of Postal Ballot and E-Voting PDF 892 KB
03 Feb 17 SSL Press Release Corporate Actions SSL Press Release Corporate Actions PDF 95.2 KB
03 Feb 17 SSL Standalone Q3 FY17 Financials SSL Standalone Q3 FY17 Financials PDF 56.4 KB
03 Feb 17 SSL Consol Q3 FY17 Financials SSL Consol Q3 FY17 Financials PDF 90.8 KB
03 Feb 17 Press Release Q3 FY 2017 Press Release Q3 FY 2017 PDF 191 KB
03 Feb 17 Intimation of change in Company Secretary Intimation of change in Company Secretary PDF 39.4 KB
02 Feb 17 Fingolimod Capsules-Tentatively Approved Fingolimod Capsules-Tentatively Approved PDF 53.3 KB
02 Feb 17 Earnings Call Intimation Earnings Call Intimation PDF 40.4 KB
01 Feb 17 Clarification on TOI report Clarification on TOI report PDF 44.3 KB
25 Jan 17 Strides Shasun announcement of Board Meeting Strides Shasun announcement of Board Meeting PDF 41.5 KB
Date Title   Report

31 Dec 16 SSL Shareholding Pattern PDF 732 KB
09 Dec 16 Strides Shasun Perrigo Press Release PDF 57 KB
25 Nov 16 Strides Shasun Press Release PDF 65 KB
03 Nov 16 Stock Exchange Intimation – Mylan settlement PDF 90 KB
28 Oct 16 Intimation of designation of Group CEO as Key Managerial Personnel PDF 36 KB
28 Oct 16 Intimation on Allotment of Equity Shares to Employees on exercise of ESO PDF 37 KB
28 Oct 16 Intimation on Dividend Policy PDF 35 KB
28 Oct 16 Intimation on Grant of Options under Strides Arcolab ESOP 2015 PDF 37 KB
28 Oct 16 SSL_Standalone Q2 FY17 Financials PDF 115 KB
28 Oct 16 SSL_Consol Q2 FY17 Financials PDF 93 KB
28 Oct 16 Press Release - Q2 FY17 PDF 189 KB
21 Oct 16 Strides Shasun Announcement of Board Meeting PDF 39 KB
30 Sep 16 SSL Shareholding Pattern PDF 672 KB
25 Aug 16 Strides Shasun receives USFDA Approval for Polyethylene Glycol 3350, Powder for Solution (OTC) PDF 61 KB
24 Aug 16 Strides Shasun receives USFDA Approval for Ranitidine Tablets PDF 55 KB
17 Aug 16 Generic Partners Holdings, Australia – transaction achieved closure PDF 122 KB
17 Aug 16 Press Release - Q1 FY17 PDF 170 KB
29 Jul 16 Report of Scrutinizer AGM PDF 210 KB
30 Jun 16 Shareholding pattern PDF 909 KB
30 Jun 16 Strides Shasun announces successful completion of US FDA inspection at its Oral Dosage Facility in Bangalore PDF 54 KB
28 Jun 16 Scrutinizer’s Report - Divestment of CRAMS Business PDF 495 KB
07 Jun 16 EIR from US FDA for Oral Dosage Facility, Bangalore PDF 28 KB
07 Jun 16 Universal Corporation, Kenya – transaction achieved closure PDF 24 KB
01 Jun 16 Strides Shasun receives USFDA Tentative Approval for Roflumilast Tablets PDF 53 KB
27 May 16 Strides Shasun receives USFDA Approval for Metronidazole Tablets PDF 55 KB
26 May 16 Strides Shasun receives USFDA Tentative Approval for Efavirenz Tablet PDF 52 KB
16 May 16 Press Release - Q4 FY16 and FY16 PDF 118 KB
16 May 16 Results presentation - Q4 FY16 and FY16 PDF 1.87 MB
16 May 16 SE Intimation - Pharmacy Alliance PDF 252 KB
16 May 16 SE Intimation - Divestment of Shasun Pharma Solutions Ltd, UK (CRAMS API Biz.) PDF 284 KB
10 May 16 Strides Shasun Announcement of Board Meeting PDF 29 KB
27 Apr 16 Update on “Acquisition of controlling stake in Universal Corporation, Kenya Receipt of approval from Competition Authority of Kenya" PDF 30 KB
26 Apr 16 Strides Shasun SE Claratification PDF 29 KB
22 Apr 16 Outcome of Postal Ballot - Approval of ESOP 2016 PDF 951 KB
06 Apr 16 SE Clarification - Economic Times article PDF 29 KB
04 Apr 16 Update on Moberg Pharma – transaction achieved closure PDF 26 KB
31 Mar 16 Strides Shareholding Pattern PDF 698 KB
21 Mar 16 SE Intimation on Postal Ballot & Evoting PDF 1.30 MB
21 Mar 16 SE Intimation on Postal Ballot & Evoting PDF 1.30 MB
07 Mar 16 Allotment of Equity Shares to Employees on exercise of ESOPs PDF 29 KB
07 Mar 16 Strides Shasun to acquire 3 brands from Moberg Pharma for USD 10 Million PDF 70 KB
23 Feb 16 Update on GMS Holdings strategic investment in Stelis Biopharma PDF 28 KB
08 Feb 16 Acquisition of Generic Partners Holdings PDF 72 KB
08 Feb 16 Acquisition of Universal Corporation, Kenya PDF 60 KB
08 Feb 16 Press Release Q3 FY16 8 Feb 2016 PDF 175 KB
08 Feb 16 SSL Consol Q3 FY 2016 Financials PDF 87 KB
08 Feb 16 SSL_Standalone Q3 FY 2016 Financials PDF 67 KB
08 Feb 16 Appointment of Mr. Shashank Sinha as CEO PDF 36 KB
03 Feb 16 Acquisition of seven brands from Johnson & Johnson - transaction achieved closure PDF 34 KB
01 Feb 16 Acquisition of CNS divisions of erstwhile Ranbaxy - transaction achieved closure PDF 52 KB
27 Jan 16 CCI approval_Johnson & Johnson PDF 25 KB
22 Jan 16 Update on “Acquisition of CNS division of erstwhile Ranbaxy” PDF 143 KB
20 Jan 16 Shareholding Pattern - 31 December 2015 PDF 808 KB
19 Jan 16 Clarification on Business Standard article PDF 35 KB
Date Title   Report

21 Dec 15 Strides Shasun receives approval from Drug Controller General of India for generic version of Sofosbuvir PDF 70.4 KB
17 Dec 15 Strides Shasun Letter to StockExchange Dec 17 2015 PDF 35.3 KB
14 Dec 15 Strides Shasun EGM-Coverpage PDF 28.7 KB
11 Dec 15 Strides Arcolab letter PDF 474 KB
12 Dec 15 Annexure 1 Outcome & Voting Results of EGM as per Reg 44(3) PDF 1.23 MB
12 Dec 15 Annexure 2 Scrutinizer Combined Report-On poll and e-voting PDF 130 KB
16 Dec 15 Strides Shasun Response to Biz Standard Article-16 Dec 2015 PDF 21.7 KB
15 Dec 15 Strides Response to NSE 15 Dec 2015 PDF 75.3 KB
15 Dec 15 Strides Response to BSE 15 Dec 2015 PDF 62.5 B
23 Nov 15 strides Shasun Stock Exchange Intimation PDF 45 KB
20 Nov 15 Strides Shasun - Intimation of EGM PDF 1.80 MB
20 Nov 15 Strides Shasun - Allotment PDF 55 KB
19 Nov 15 Strides Arcolab_Name change letter PDF 51 KB
05 Nov 15 Strides Arcolab_Intimation to Stock Exchange PDF 56 KB
29 Oct 15 FIPB Approval Intimation to Stock Exchange PDF 100 KB
27 Oct 15 Press Release Q2 FY16 INR PDF 154 KB
27 Oct 15 Consol SEBI Q2 2015-16 PDF 91 KB
27 Oct 15 Standalone SEBI Q2 2015-16 PDF 74 KB
06 Oct 15 Intimation of Postal Ballot PDF 1.36 MB
28 Sept 15 Intimation to SE_Fund Raising PDF 47 KB
19 Sept 15 Strides Arcolab acquires CNS divisions of erstwhile Ranbaxy PDF 92 KB
16 Sept 15 Update on Scheme of Amalgamation of Shasun and Strides PDF 48 KB
31 Aug 15 Update on ‘Acquisition of a generic pharmaceutical business in Australia PDF 44 KB
31 July 15 Strides Arcolab receives ANDA approval from US FDA for Benzonatate Softgel Capsules PDF 124 KB
30 July 15 SAL - Consolidated financial statements PDF 78 KB
30 July 15 SEBI Standalone PDF 78 KB
30 July 15 Strides Arcolab announces Q1 FY16 Results PDF 492 KB
10 July 15 Strides arcolab scrutinizer's report PDF 560 KB
10 July 15 Strides arcolab combined result clause 35 format PDF 120 KB
10 July 15 Strides arcolab outcome of postal ballot cover note PDF 138 KB
19 June 15 Strides Intimation PDF 53 KB
17 June 15 Strides Arcolab Update on Scheme of Amalgamation PDF 50 KB
22 May 15 Strides Arcolab announces Q4 FY15 and FY15 Results PDF 535 KB
21 May 15 Strides inks agreements to acquire a generic pharmaceutical business in Australia and related assets from Aspen for approximately A$380 million
Acquisition to be EPS accretive immediately 		PDF 82.2 KB
15 May 15 Strides Arcolab receives ANDA approval from US FDA for Lamivudine and Zidovudine Tablets PDF 63.8 KB
15 April 15 Strides Arcolab receives ANDA approval from US FDA for Polyethylene Glycol 3350, Sodium Chloride, Sodium Bicarbonate and Potassium Chloride for Oral Solution. PDF 79 KB
27 Feb 15 Launch of generic drug Sofosbuvir in India under the brand name 'Virso' PDF 56.8 KB
02 Feb 15 Statement Of Standalone Unaudited Results For The Nine Months Ended December 31, 2014. PDF 67 KB
02 Feb 15 Strides Arcolab reports Q3 FY 2014-15 Results Pharma Revenues at INR 3,261 Mn with an EBITDA of INR 664 Mn EBITDA Margin at 20%. PDF 127 KB
20 Jan 15 Strides Arcolab signs Agreement with Gilead Sciences to Manufacture and Distribute Tenofovir Alafenamide (TAF) based HIV treatments in 112 Developing Countries. PDF 57 KB
13 Jan 15 Singapores Economic Development Board grants International Headquarter Status to Strides Pharma Global Pte. Ltd. Singapore. PDF 82 KB
Date Title   Report

16 Dec 14 Strides Arcolab receives US FDA approval for Calcitriol Softgel Capsules. PDF 65 KB
03 Dec 14 Stelis Biopharma Begins Construction of Multi-Product Biologics Facility At Bioxcell Biotechnology Park, Johor, Malaysia. PDF 210 KB
27 Nov 14 Strides Arcolab Press Release MMV announces collaborations with Cipla and Strides. PDF 72 KB
20 Nov 14 Appointment of Mr. Abhaya Kumar PDF 43 KB
07 Nov 14 Strides Arcolab reports Robust Q2 FY 2014-15 Results. PDF 126 KB
01 Oct 14 Strides Arcolab clarifies on the Import Alert published on the US FDA website regarding its subsidiary Beltapharm SpA, Italy. PDF 58 KB
29 Sept 14 Strides Arcolab announces strategic Investor for its greenfield Biotech project. PDF 87 KB
29 Sept 14 Strides Arcolab and Shasun Pharmaceuticals combine to accelerate strategy and growth. PDF 142 KB
15 Sept 14 Strides partners with Gilead Sciences Inc, to bring Hepatitis C cure to 91 developing countries. PDF 88 KB
26 Aug 14 Strides Arcolab receives US FDA approval for Buspirone Tablets. PDF 92 KB
25 Jul 14 Strides Arcolab announces Q1 FY 2014-15 Results. PDF 73 KB
23 Jul 14 Strides Arcolab receives USFDA approval for Tacrolimus Capsules. PDF 92 KB
21 Jul 14 Strides Arcolab acquires 'Raricap' and India Branded Generic Business of Bafna. PDF 82 KB
16 Jul 14 Strides Arcolab makes strategic investment in Oncobiologics Inc., USA. PDF 210 KB
25 Jun 14 Strides Arcolab receives US FDA approval for Imiquimod Cream. PDF 77 KB
06 Jun 14 Strides Arcolab receives US FDA approval for Methoxsalen Softgel Capsules. PDF 78 KB
23 May 14 Strides financial results for the Quarter ending March 31, 2014 and Financial Year ending March 31, 2014. PDF 81 KB
25 Apr 14 Strides reports continued US FDA approval Status for Oral Dosage Facility. PDF 76 KB
Date Title   Report

10 Dec 13 Update on Agila Transaction. PDF 107 KB
5 Dec 13 Strides Arcolab completes sale of Agila Specialties division to Mylan. PDF 113 KB
14 Nov 13 Strides Arcolab announces Q3'13 Results. PDF 84 KB
23 Oct 13 Stelis Biopharma signs a Research Collaboration Agreement with Bio-Scaffold International Pte Ltd to develop scaffolds loaded with BMP and stem cells for various medical applications. PDF 124 KB
18 Sep 13 Strides Arcolab announces US FDA approval for its Italian Semi-solids and Oinment facility. PDF 75 KB
1 Aug 13 Strides Arcolab receives ANDA approval from USFDA for Tenofovir Disoproxil Fumarate and Emtricitabine Tablets. PDF 76 KB
25 Jul 13 Global Pharma business in line with Guidance. PDF 81 KB
25 Jun 13 Strides announces WHO pre-qualification for Artemether+Lumifantrine (AL). PDF 68 KB
25 Apr 13 Strides reports strong quarterly performance - Standalone Financial Highlights. PDF 80 KB
16 Apr 13 Pfenex Inc. and Agila Biotech Private Limited Announce Joint Venture to Develop Biosimilar Products for the Global Market. PDF 85 KB
19 Mar 13 Malaysian Bio-Xcell SDN BHD seals a deal exceeding US$35M (~RM107M) with AGILA Biotech SDN BHD during Biopharma Asia 2013. PDF 98 KB
06 Mar 13 Agila Receives Us FDA approval for Zoledronic Acid Injection. PDF 86 KB
28 Feb 13 Strides Arcolab to Sell AGILA Specialties Division to Mylan INC. For An Aggregate Sum of US$1,600 Million in Cash and Potential Additional Consideration Of Up To US$250 Million. PDF 355 KB
28 Feb 13 Strides reports Continued Strong Operational Performance. PDF 147 KB
Date Title   Report

05 Dec 12 Strides Arcolab and Lilly Enter Strategic Partnership to Deliver High-Quality, Branded Generic Cancer Medicines for Emerging Markets. PDF 90 KB
19 Oct 12 Strides reports Continued Strong Operational Performance in Q3'12. PDF 93 KB
18 Oct 12 Strides Arcolab Receives 2 More Approvals For Oncology Products from USFDA. PDF 84 KB
13 Sep 12 Strides Arcolab Announces US FDA Approval of Its Polish Sterile Injectable Facility. PDF 81 KB
03 Sep 12 Strides Arcolab Receives US FDA Approval For Vinorelbine Injection. PDF 86 KB
29 Aug 12 Strides Arcolab Receives US FDA Approval For Topotecan Injection. PDF 86 KB
8 Aug 12 Strides Arcolab Receives Us FDA Approval For Oxaliplatin Injection. PDF 87 KB
6 Aug 12 Strides collaborates with Gilead Sciences. PDF 67 KB
27 Jul 12 Strides reports Strong Operational Performance in Q2'12. PDF 133 KB
24 Jul 12 Proparco Investment in Strides' African Arm. PDF 67 KB
20 Jul 12 Strides Arcolab Receives US FDA Approval For Fluorouracil Injection. PDF 77 KB
27 Jun 12 Strides redeems FCCBs due 2012 Net Debt / Equity at 0.75. PDF 100 KB
11 Jul 12 Agila Announces Entry Into Canadian Injectable Market. PDF 79 KB
27 Jun 12 Strides redeems FCCBs due 2012 Net Debt / Equity at 0.75. PDF 100 KB
10 May 12 Strides Arcolab Receives US FDA Approval for Acetazolamide Injection, USP. PDF 89 KB
26 Apr 12 Strides delivers Robust Q1'12 Performance. PDF 133 KB
26 Apr 12 Strides acquires US FDA approved Sterile Formulations facility. PDF 76 KB
19 Apr 12 Strides Arcolab Receives US FDA Approval Forcisplatin Injection. PDF 85 KB
11 Apr 12 Strides Arcolab Receives US FDA Nod For Vancomycin Oral Capsules. PDF 77 KB
3 Apr 12 Strides Arcolab Announces Health Canada Approval for Tobramycin Injection. PDF 77 KB
30 Mar 12 Strides Arcolab Receives US FDA Approval For Methotrexate Injection. PDF 84 KB
27 Feb 12 Audited Financial Results Year Ended December 31, 2011. PDF 152 KB
24 Feb 12 Strides Arcolab Announces Us FDA Approval For Its 'Brazilian Sterile Penems Facility'. PDF 93.2 KB
24 Jan 12 Sale of generic pharmaceutical operations in Australia and Southeast Asia for AU$375 million - Analyst Presentation PDF 1.33 MB
24 Jan 12 Strides Arcolab Sells Its Generic Pharmaceutical Operations In Australia and Southeast Asia to Watson Pharmaceuticals for Au$ 375 Million. PDF 79 KB
Date Title   Report

22 Dec 11 Strides Press Release Sterile Plant Approval and Fludarabine Approval. PDF 104 KB
15 Dec 11 Strides Press Release Cytarabine Approval. PDF 99 KB
24 Nov 11 Approval Momentum for Oncology Products Continues With Two More USFDA Approvals. PDF 106 KB
11 Nov 11 Strides Arcolab receives US FDA approval for Carboplatin Injection. PDF 178 KB
02 Nov 11 Strides Arcolab Receives US FDA Approval for Doxorubicin Injection. PDF 87 KB
24 Oct 11 Strides Results Pack Financials for Q3 '11. PDF 974 KB
24 Oct 11 Strides delivers Superior Q3 '2011 Financials Ups Full Year Guidance PDF 125 KB
20 Oct 11 Strides Arcolab Receives US FDA Approval For Bupivacaine Hydrochloride Injection, USP PDF 77 KB
10 Oct 11 Strides Arcolab Receives US FDA Approval for Cladribine Injection PDF 77 KB
03 Oct 11 Strides Arcolab Receives US FDA Approval For Clindamycin Injection, USP PDF 74 KB
30 Sep 11 Strides Oncology Approvals Gain Momentum With Two More USFDA Approvals PDF 88 KB
15 Sep 11 Strides Announces European Approval For Oxaliplatin Injection PDF 90 KB
14 Sep 11 Strides continued US FDA Approval Status For Oral Dosage Facility PDF 66 KB
28 July 11 Strides Arcolab Announces US FDA Approval For Acarbose Tablets PDF 106 KB
26 July 11 Strides Arcolab Announces US FDA Approval For Gemcitabine For Injection USP PDF 77 KB
1 July 11 Strides Announces European Approval For Its Oral Dosage Facility In Its Oncology Complex PDF 50 KB
1 July 11 Strides Arcolab Receives US FDA Approval For Polymyxin Injection PDF 50 KB
29 Jun 11 Strides Arcolab Joins The Malaysian BIO-XCELL Ecosystem PDF 50 KB
21 Jun 11 Strides Arcolab Receives US ADA Approval For Levofloxacin Injection PDF 50 KB
5 May 11 Strides Arcolab Receives US FDA Approval For Midazolam Injection Multi-Dose Vials PDF 50 KB
2 May 11 Strides announces US FDA approval for its Oncology facility in Bangalore PDF 50 KB
25 Apr 11 Results Pack Financials for Q1 2011 PDF 50 KB
25 Apr 11 Strides Announces Q1 ‘2011 Financial Results PDF 50 KB
18 Apr 11 Strides Arcolab Announces US FDA Approval For Its ‘New Sterile Injectable Facility PDF 50 KB
13 Apr 11 Strides Arcolab Receives US FDA Nod To Commercialize First Liquid Injectable Product From Its New Facility PDF 50 KB
4 Mar 11 Strides Announces First European Approval For Oncology Product PDF 50 KB
1 Mar 11 Strides arcolab receives US FDA nod to commercialize first sterile product from new facility PDF 50 KB
24 Feb 11 Results Pack Financials for the year 2010 PDF 50 KB
24 Feb 11 Press Release PDF 50 KB
20 Jan 11 AGILA Signs Agreement with Biochimico To Set Up A Joint Venture Company In Brazil. PDF 50 KB
18 Jan 11 Strides Arcolab announces US FDA Approval for additional Adenosine Injection USP PDF 50 KB
Date Title   Report

10 Dec 10 Strides Arcolab Announces US FDA Approval for Lidocaine Hydrochloride Injection. PDF 50 KB
09 Dec 10 Strides acquires controlling stake in Inbiopro. PDF 50 KB
01 Dec 10 Strides Arcolab Announces US FDA Approval Of Midazolam Hydrochloride Injection. PDF 50 KB
25 Nov 10 Strides Specialties Rebranded As Agila Specialties. PDF 50 KB
29 Oct 10 Strides Arcolab receives ANDA approval from US FDA for Lamivudine and Zidovudine under PEPFAR scheme. DF 50 KB
27 Oct 10 Strong Performance Across Business Divisions Steers 35% Growth In Revenue For Strides. PDF 50 KB
26 Oct 10 Strides' Generic Oseltamivir Receives WHO Prequalification for treatment of H1N1. PDF 50 KB
04 Oct 10 Strides Arcolab Records 50th Anda Approval 2 More Anda Approvals Received. PDF 50 KB
04 Aug 10 Strides Arcolab announces US FDA approval for Ergocalciferol Capsules 1.25mg first approval for a Soft Gelatine Product. PDF 50 KB
03 Aug 10 Strides' Sterile Carbapenems Facility In Campos, Brazil receives MHRA Approval. PDF 50 KB
30 Jul 10 Strides Arcolab Announces US FDA Approval of Sumatriptan Succinate Injection. PDF 50 KB
30 Jul 10 Strides Arcolab Announces US FDA Approval of Rocuronium Bromide Injection. PDF 50 KB
27 Jul 10 Strides today announced Q2-10 results. DF 50 KB
13 Jul 10 Strides Annual Report 2009 Wins LACP Platinum Award. PDF 50 KB
18 May 10 Strides Arcolab Receives ANDA approval from US FDA for Abacavir Sulfate Tablets, 300mg under PEPFAR Scheme. PDF 50 KB
14 May 10 Strides and Pfizer Strengthen Partnership. PDF 50 KB
13 May 10 Strides Arcolab announces US FDA Approval of Vecuronium Bromide for Injection. PDF 50 KB
12 May 10 Strides Arcolab announces US FDA Approval Of Bacitracin For Injection, USP. PDF 50 KB
11 May 10 Manish Gupta to lead Pharma Business at Strides Arcolab. Manish Gupta to lead Pharma Business at Strides Arcolab PDF 50 KB
22 Apr 10 Strides Arcolab Announces US FDA Tentative Approval Of Additional Adenosine Injection. Strides Arcolab Announces US FDA Tentative Approval Of Additional Adenosine Injection PDF 50 KB
22 Apr 10 Strides today announced Q1'10 financials. PDF 50 KB
21 Apr 10 Strides Arcolab Announces US FDA Approval For Metoprolol Tartrate Injection. Strides Arcolab Announces US FDA Approval For Metoprolol Tartrate Injection PDF 50 KB
20 Apr 10 Strides redeems USD 34 Million FCCBs due 2010. Strides redeems USD 34 Million FCCBs due 2010 PDF 50 KB
19 Apr 10 Strides Arcolab Announces US FDA Approval For Mesna Injection. Strides Arcolab Announces US FDA Approval For Mesna Injection PDF 50 KB
14 Apr 10 Strides Arcolab Announces US FDA Approval For Granisetron Hydrochloride Injection. Strides Arcolab Announces US FDA Approval For Granisetron Hydrochloride Injection PDF 50 KB
18 Mar 10 Strides revises guidance upwards for FY 2010. PDF 50 KB
18 Mar 10 Strides and Aspen restructure Oncology arrangements. Strides and Aspen restructure Oncology arrangements PDF 50 KB
04 Mar 10 Strides to acquire Campos facility in Brazil from Aspen. Strides to acquire Campos facility in Brazil from Aspen PDF 50 KB
24 Feb 10 Results Pack Financials for the year 2009. Results Pack Financials for the year 2009 PDF 50 KB
24 Feb 10 Audited Financial Results for the Year ended 31 December 2009. Audited Financial Results for the Year ended 31 December 2009 PDF 50 KB
09 Feb 10 Strides Arcolab announces US FDA approval for Labetalol Hydrochloride injection, USP – total Approvals in sterile space at 18. Strides Arcolab announces US FDA approval for Labetalol Hydrochloride injection, USP – total Approvals in sterile space at 18 PDF 50 KB
20 Jan 10 Strides Arcolab appoints Venkat Iyer To Board of Directors. Strides Arcolab appoints Venkat Iyer To Board of Directors PDF 54 KB
6 Jan 10 Pfizer and Strides Arcolab to Collaborate on Generic Products. Pfizer and Strides Arcolab to Collaborate on Generic Products. PDF 74 KB